|
    ACIU U.S.: Nasdaq

    AC Immune S.A.

    ACIUUS
    After Hours
    Back To Top
    Last Updated: Jul 23, 2021 7:20 p.m. EDT Delayed quote

    $ 7.53

    0.07 0.94%
    After Hours Volume: 16.7K
    Close Chg Chg %
    $7.46 -0.01 -0.13%
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 181.96K 65 Day Avg: 490.77K
    37% vs Avg
    7.28 Day Range 7.60
    4.42 52 Week Range 12.50

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ACIU Overview

    Performance

    5 Day
    • 0.95%
    1 Month
    • -8.80%
    3 Month
    • 10.03%
    YTD
    • 44.29%
    1 Year
    • 8.12%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 3 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    AC Immune Updates on Vaccine Candidates in Alzheimer's Disease

    AC Immune stock price target raised to $8.00 from $5.50 at UBS

    AC Immune stock price target cut to $4 from $16 at UBS

    AC Immune downgraded to neutral from buy at UBS

    AC Immune started at buy with $16 stock price target at UBS

    AC Immune started at outperform with $18 stock price target at Leerink

    Read full story

    Charting the Market

    Read full story

    Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’

    AC Immune SA surges 11% on presentation of Eli Lilly Alzheimer's drug trial results

    Read full story

    What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors

    AC Immune started at outperform with $22 stock price target at Leerink Partners

    • Other News
    • Press Releases

    Leerink Partners Reiterates Their Buy Rating on AC Immune SA (ACIU)

    on SmarterAnalyst

    H.C. Wainwright Reiterates Their Buy Rating on AC Immune SA (ACIU)

    on SmarterAnalyst

    AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates

    on Zacks.com

    AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade

    on Zacks.com

    AC Immune SA (ACIU) Gets a Buy Rating from Leerink Partners

    on SmarterAnalyst

    AC Immune SA (ACIU) Gets a Buy Rating from H.C. Wainwright

    on SmarterAnalyst

    H.C. Wainwright Remains a Buy on AC Immune SA (ACIU)

    on SmarterAnalyst

    Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

    on Zacks.com

    AC Immune SA (ACIU) Receives a Buy from H.C. Wainwright

    on SmarterAnalyst

    ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today

    on InvestorPlace.com

    H.C. Wainwright Thinks AC Immune SA’s Stock is Going to Recover

    on SmarterAnalyst

    AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

    on Zacks.com

    Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

    on Zacks.com

    AC Immune's Candidate Fails in Alzheimer's Disease Study

    on Zacks.com

    Do Options Traders Know Something About AC Immune (ACIU) Stock We Don't?

    on Zacks.com

    Companies Big and Small Seeking $10 Billion Alzheimer's Opportunity

    on GuruFocus.com

    Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

    on Zacks.com

    Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

    on Zacks.com

    AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

    on Zacks.com

    All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy

    on Zacks.com

    AC Immune S.A.

    AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

    Competitors

    Name Chg % Market Cap
    Ono Pharmaceutical Co. Ltd. ADR -0.59% $11.34B
    Omeros Corp. -0.35% $884.44M
    Competitor Data Provided ByCapital Cube Logo